BioVie to present data on NE3107 in DNA methylation of specific genes

BioVie announced that a poster detailing the genetic basis for how its drug candidate NE3107 regulated specific genes in a manner significantly correlated with observed cognitive and biomarker improvements will be presented this weekend at the Alzheimer’s Associate’s International Conference to be held in Amsterdam July 16-20, 2023. In a poster presentation titled Treatment-Induced Epigenetic Modifications in MCI and Probable Alzheimer’s, presenters will show how patients with clinical dementia treated with NE3107 for 3 months saw significant reductions in the level of DNA methylation, and that such reductions were significantly correlated with observed improvements in various cognitive measures and biomarkers. Inflammation has been shown to be associated with the hypermethylation of our DNA, which in turn has been shown to impact a wide range of diseases, including various forms of cancers, age-related cognitive impairment and dementia, Parkinson’s disease, cardiovascular disease, COPD and respiratory disease, chronic kidney disease, inflammatory bowel disease, sepsis, and many others. The new data to be presented details how NE3107 may potentially change or affect the degree of methylation of specific genes that are correlated with various markers of disease.